Literature DB >> 11407977

HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.

K S Lang1, C C Caroli, A Muhm, D Wernet, A Moris, B Schittek, E Knauss-Scherwitz, S Stevanovic, H G Rammensee, C Garbe.   

Abstract

Vitiligo is a skin and hair disorder characterized by circumscribed depigmented lesions due to lack of melanocytes in the respective areas. It has been suggested that vitiligo is caused by an autoimmune-mediated destruction of melanocytes. Recently, the presence of a high frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in the peripheral blood of patients with vitiligo was reported. Our study examines the frequency of melanocyte-specific cytotoxic T lymphocytes in vitiligo patients and its relationship to disease activity. Thirty-two patients with moderate to active vitiligo and 17 control subjects were included. Melanocyte specific reactive CD8(+) T cells were identified by enzyme-linked immunospot assay after stimulation with five peptides from gp100, four peptides from MelanA/MART1, and two peptides from tyrosinase. In selected patients, intracellular interferon-gamma staining for the detection of specific reactive CD8(+) T cells was additionally performed. In seven of 10 patients (70%) with actively progressive disease CD8(+) T cells directed against melanocyte epitopes were detected, whereas only in four of 22 patients (18%) with moderate disease activity such specific reactivity was found. MelanA/MART1 peptides were immunodominant in nine patients reacting against EAAGIGILTV and three patients reacting against ILTVILGVL. Intracellular interferon-gamma staining confirmed the findings obtained by the enzyme-linked immunospot technique. The present study supports the hypothesis that vitiligo is a cytotoxic T lymphocyte-mediated autoimmune disease. The presence of melanocyte-specific reactive CD8(+) T cells seems to be closely related to disease activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407977     DOI: 10.1046/j.1523-1747.2001.01363.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  31 in total

Review 1.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

2.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

Review 3.  The convergence theory for vitiligo: A reappraisal.

Authors:  Roopal V Kundu; Julia M Mhlaba; Stephanie M Rangel; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2018-06-28       Impact factor: 3.960

4.  The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo.

Authors:  E Helen Kemp; Elizabeth A Waterman; Brian E Hawes; Kim O'Neill; Raju V S R K Gottumukkala; David J Gawkrodger; Anthony P Weetman; Philip F Watson
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

Review 5.  Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase.

Authors:  Karen Taraszka Hastings; Peter Cresswell
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

6.  GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.

Authors:  Matthew P Rausch; Kari R Irvine; Paul A Antony; Nicholas P Restifo; Peter Cresswell; K Taraszka Hastings
Journal:  J Immunol       Date:  2010-07-28       Impact factor: 5.422

7.  Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo.

Authors:  S You; Y-H Cho; J-S Byun; E-C Shin
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

8.  Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies.

Authors:  Milos Aleksic; Nathaniel Liddy; Peter E Molloy; Nick Pumphrey; Annelise Vuidepot; Kyong-Mi Chang; Bent K Jakobsen
Journal:  Eur J Immunol       Date:  2012-10-16       Impact factor: 5.532

9.  Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1.

Authors:  E A Waterman; E H Kemp; D J Gawkrodger; P F Watson; A P Weetman
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

10.  Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.

Authors:  David Escors
Journal:  New J Sci       Date:  2014-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.